Stocks poised to move as this corner of the cancer therapy market heats up
Radiopharmaceuticals seek to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor.
Source: cnbc.com
Stay updated with breaking news from Andy Hsieh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Radiopharmaceuticals seek to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor.
Lantheus Holdings, Inc. beats earnings expectations. Reported EPS is $1.69, expectations were $1.55. Lantheus Holdings, Inc.
EXEL earnings call for the period ending March 31, 2024.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
This high-flying biotech stock has captured investors' attention for all the right reasons.